Abstract
Objective
To compare insertion pain and ease of insertion in participants with a prior caesarean
delivery having copper intrauterine device (IUD) after pretreatment with isonicotinic
acid hydrazide (INH) 900 mg vaginally or placebo.
Study design
From September 2020 to September 2021, we conducted a randomized, double-blind, placebo-controlled
experiment at Aswan University Hospital in Egypt with participants who were delivered
solely by caesarean delivery and desired copper T380A IUD insertion. The participants
were randomly assigned to either vaginal INH or placebo six hours before IUD insertion
in a 1:1 ratio. The primary objective of the research was the individuals' self-reported
pain during cervical tenaculum placement, sound insertion, IUD insertion, and 5 minutes
after the placement, as measured by a 10-cm visual analogue scale (VAS). Our secondary
outcomes were ease of insertion, satisfaction, the need for analgesics, and adverse
effects. IUD insertion ease was graded from 0 to 10 on a 10-cm VAS scale, with 0 suggesting
very easy insertion and 10 denoting extremely difficult insertion.
Results
When compared to the placebo group, the INH group experienced considerably less pain
during IUD insertion , lower median ease of insertion score , and better satisfaction . The two groups had comparable side effects.
Conclusions
Vaginal INH administered before IUD insertion reduce the amount of discomfort participants
feel throughout the process in individuals who had previously only been delivered
via CD. It also has the potential to make insertion easier.
Implications
In participants who were delivered solely by CD before, vaginal INH given prior to
IUD placement reduces the amount of discomfort participants experience throughout
the procedure. Furthermore, it could increase the ease of insertion.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Increasing use of long-acting reversible contraception to decrease unplanned pregnancy.Obstetr Gynecol Clin. 2015; 42: 557-567
- The latest in teen pregnancy prevention: long-acting reversible contraception.J Pediatr Health Care. 2018; 32: e91-e97
- Interventions for the prevention of pain associated with the placement of intrauterine contraceptives: an updated review.Acta Obstet Gynecol Scand. 2019; 98: 1500-1513
- Immediate postpartum insertion of intrauterine device for contraception.Cochrane Database Syst Rev. 2015;
- Vaginal misoprostol prior to intrauterine device insertion in women delivered only by elective cesarean section: a randomized double-blind clinical trial.Contraception. 2017; 95: 538-543
- Medications to ease intrauterine device insertion: a systematic review.Contraception. 2016; 94: 739-759
- Beliefs and Use of Intrauterine Devices (IUDs) among women's health care providers.J Nurse Practitioners. 2019; 15: 682-687
- Nitric oxide donors induce ripening of the human uterine cervix: a randomised controlled trial.BJOG. 1997; 104: 1054-1057
- Isonicotinic acid hydrazide (INH): a new agent for cervical ripening at term.J Obstet Gynaecol. 2015; 35: 251-254
- Protective role of caffeic acid phenethyl ester and erdosteine on activities of purine-catabolizing enzymes and level of nitric oxide in red blood cells of isoniazid-administered rats.Toxicol Ind Health. 2008; 24: 519-524
- Intravaginal isonicotinic acid hydrazide (INH) versus misoprostol for cervical ripening prior to hysteroscopy.Obstetr Gynecol Sci. 2020; 63: 514-520
- World Health Organization. Reproductive Health. Medical eligibility criteria for contraceptive use.World Health Organization, 2010
Insertion technique for the Copper T380A IUD | RHL n.d. 316 https://extranet.who.int/rhl/resources/videos/insertion-technique-copper-t380a-iud 317 (accessed October 8, 2019).
- What is a “clinically meaningful” reduction in pain?.Pain. 2001; 94: 131-132
- Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain.J Pain. 2003; 4: 407-414
- Higher dose cervical 2% lidocaine gel for IUD insertion: a randomized controlled trial.Contraception. 2013; 88: 730-736
- Chemical ripening of the cervix with intracervical application of sodium nitroprusside: a randomized controlled trial.Hum Reprod. 2000; 15: 2224-2227
- Intracervical application of the nitric oxide donor isosorbide dinitrate for induction of cervical ripening: a randomised controlled trial to determine clinical efficacy and safety prior to first trimester surgical evacuation of retained products of conception.BJOG. 2005; 112 (Dec): 1615-1619
- Intracervical sodium nitroprusside versus vaginal misoprostol in first trimester surgical termination of pregnancy: a randomized double-blinded controlled trial.Hum Reprod. 2005; 20: 829-833
- Clinical significance of reported changes in pain severity.Ann Emerg Med. 1996; 27: 485-489
- Prospective validation of clinically important changes in pain severity measured on a visual analog scale.Ann Emerg Med. 2001; 38: 633-638
- The effect of nitroprusside on the IUD insertion experience in nulligravid women: a pilot study.Contraception. 2012; 86: 320
- The effect of nitroglycerin on the IUD insertion experience in nulliparous women: a pilot study.Contraception. 2014; 90: 60-65
Article info
Publication history
Published online: February 17, 2022
Accepted:
January 31,
2022
Received in revised form:
January 27,
2022
Received:
September 13,
2021
Footnotes
☆Conflicts of Interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
aFunding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
